|
ADBICA
ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. ADBICA is a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 0.69 nM and 1.8 nM respectively. Legal Status As of October 2015 ADBICA is a controlled substance in China. See also * 5F-AB-PINACA * 5F-ADB * 5F-ADBICA * 5F-AMB * 5F-APINACA * AB-FUBINACA * AB-CHFUPYCA * AB-CHMINACA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADB-P7AICA * APICA * ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-ADBICA
5F-ADBICA (also known as 5F-ADB-PICA) is an indole-based synthetic cannabinoid that is a potent agonist at CB1 receptors and CB2 receptors with EC50 values of 0.77 nM and 1.2 nM respectively. Legal status China As of October 2015 5F-ADBICA is a controlled substance in China. See also * ADBICA * ADB-PINACA * APICA * PX-1 * SDB-001 * STS-135 STS-135 ( ISS assembly flight ULF7) was the 135th and final mission of the American Space Shuttle program. It used the orbiter '' Atlantis'' and hardware originally processed for the STS-335 contingency mission, which was not flown. STS-135 ... References Cannabinoids Designer drugs Indolecarboxamides Organofluorides {{cannabinoid-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-FUBINACA
ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The name is an acronym for N-(1-Amino-3,3-Dimethyl-1-oxoButan-2-yl)-1-(4-FlUoroBenzyl)-1H-INdAzole-3-CarboxAmide. The (''S'')-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ... of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-FUBINACA
AB-FUBINACA ( AMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported. Its use has been linked to hospitalizations and deaths. Legality United States of America It was designated as a Schedule I controlled substance in the United States in January 2014. Finland In Finland AB-FUBINACA is scheduled in government decree on psychoactive substances banned from the consumer market as of 19 October 2017. Germany It is an Anlage II controlled substance in Germany as of November 2014. China Since October 2015 AB-FUBINACA is a controlled subs ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-PINACA
ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBINACA, this compound incorporates the unnatural amino acid ''tert''-leucine. Side effects ADB-PINACA has been linked to multiple hospitalizations and deaths due to its use. Metabolism Nineteen ADB-PINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic reactions included pentyl hydroxylation, hydroxylation followed by oxidation (ketone formation), and glucuronidation. Legality ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015. In the United States, it is a Schedule I controlled substance The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (''K''i = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (''K''i = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 1.5x more potent. There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. Legal status Germany AB-PINACA is an Anlage II controlled substance in Germany as of November 2014. Singapore It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015. United States It is a Schedule I controlled substance in the United States. China It is a controlled substance in China as of October 2015. France It is a contr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-AB-PINACA
5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug. 5F-AB-PINACA has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.48 nM and 2.6 nM respectively. Its metabolism has been described in literature. Legality China As of October 2015 5F-AB-PINACA is a controlled substance in China. Germany 5F-AB-PINACA is an Anlage II controlled substance in Germany as of May 2015. Singapore It is also controlled under the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015. See also * 5F-ADB * 5F-AMB * 5F-CUMYL-PINACA * AB-FUBINACA * AB-CHFUPYCA * AB-PINACA * ADB-CHMINACA * ADB-FUBINACA * ADB-PINACA * ADBICA * APICA * APINACA * MDMB-CHMICA * PX-3 PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonis ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Synthetic Cannabis
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that bind to the same receptors to which cannabinoids ( THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids (obtained by chemical synthesis) or synthetic endocannabinoids from which they are distinct in many aspects. Typically, synthetic cannabinoids are sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the United States and United Kingdom since 2016. They have been marketed as herbal incense, or "herbal smoking blends", and sold under common names such as K2, spice, and synthetic marijuana. They are often labeled "not for human consumption" for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid legal restrictions on cannabis, making synthetic cannabinoids designer drugs. Most s ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-CHMINACA
AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor (''K''i = 0.78 nM) and CB2 receptor (''K''i = 0.45 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent. Continuing the trend seen in other cannabinoids of this generation, such as AB-FUBINACA and AB-PINACA, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue. Side effects There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid. Legal status In 2015, AB-CHMINACA became a Schedule I controlled substance in the United States. AB-CHMINACA is an Anlage II controlled substance in Germany as of May 2015. As of October 2015 AB-CHMINACA is a controlled substance in China. AB-CHMINACA is illegal in Switzerland as of December 2015. AB-CHMINACA is a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-P7AICA
ADB-P7AICA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first identified by the DEA in early 2021. See also * 5F-CUMYL-P7AICA * ADBICA * ADB-PINACA ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBIN ... References {{Cannabinoids Cannabinoids Designer drugs Pyrrolopyridines Tert-butyl compounds ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ADB-CHMINACA
ADB-CHMINACA (also known as ADMB-CHMINACA and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. Side effects There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. Legal status In the United States, ADB-CHMINACA is a Schedule I controlled substance. Prior to its listing at the federal level in 2018, Louisiana placed ADB-CHMINACA on its Schedule I list by emergency scheduling in 2014. Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014. ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015. ADB-CHMINACA is illegal in Switzerland as o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
AB-CHFUPYCA
AB-CHFUPYCA (also AB-CHMFUPPYCA) is a compound that was first identified as a component of synthetic cannabis products in Japan in 2015. The name "AB-CHFUPYCA" is an acronym of its systematic name ''N''-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(CycloHexylmethyl)-3-(4-FlUorophenyl)-1''H''-PYrazole-5-CarboxAmide. There are two known regioisomers of AB-CHFUPYCA: 3,5-AB-CHMFUPPYCA (pictured) and 5,3-AB-CHMFUPPYCA. The article refers to both 3,5-AB-CHMFUPPYCA and 5,3-AB-CHMFUPPYCA as AB-CHMFUPPYCA isomers, so AB-CHMFUPPYCA and AB-CHFUPYCA are not names for a unique chemical structure. AB-CHFUPYCA contains some similar structural elements to other synthetic cannabinoids such as 5F-AB-FUPPYCA, JWH-307, JWH-030, JWH-147, AB-PINACA. It may be considered an analog of the traditional pyrazole Pyrazole is an organic compound with the chemical formula, formula . It is a heterocycle characterized as an azole with a 5-membered ring of three carbon atoms and two adjacent nitrogen atoms, whi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5F-AMB
5F-AMB (also known as 5F-MMB-PINACA and 5F-AMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in early 2014. Although only very little pharmacological information about 5F-AMB itself exists, its 4-cyanobutyl analogue (instead of 5-fluoropentyl) has been reported to be a potent agonist for the CB1 receptor (''K''I = 0.7 nM). Side effects 5F-AMB intoxication caused one fatality on its own, another through ketoacidosis in combination with AB-CHMINACA, AB-FUBINACA, AM-2201, 5F-APINACA, EAM-2201, JWH-018, JWH-122, MAM-2201, STS-135 and THJ-2201 and another fatality in combination with AB-CHMINACA and Diphenidine. Legality In the United States, 5F-AMB is a Schedule I controlled substance. 5F-AMB is an Anlage II controlled substance in Germany as of May 2015. Sweden's public health agency suggested classify ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
